TBK1 and HIV-1 infection: In line with this possibility, recent studies suggest that mDCs treated with adjuvants targeting TBK1 are associated with reduced depletion of CD4+ T cells and polyfunctional HIV-1 specific CD8+ T cells in humanized mice after HIV-1 infection (33).